Phase 3 clinical trials verified that serum FGF21 was elevated in pemafibrate-treated groups [15], possibly leading to improved liver function [17,20] as well as improvements in inflammation and steatosis of the liver [30,31]. This evidence concerns the gene FGF21 and steatosis.